> Details

Gouyou, Baptiste [Author]; Grün, Katja [Author]; Kerschenmeyer, Anne [Author]; Villa, Allessandra [Author]; Matasci, Mattia [Author]; Schrepper, Andrea [Author]; Pfeil, Alexander [Author]; Bäz, Laura [Author]; Jung, Christian [Author]; Schulze, Paul Christian [Author]; Neri, Dario [Author]; Franz, Marcus [Author]

Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Therapeutic Evaluation of Antibody-Based Targeted Delivery of Interleukin 9 in Experimental Pulmonary Hypertension
  • Contributor: Gouyou, Baptiste [Author]; Grün, Katja [Author]; Kerschenmeyer, Anne [Author]; Villa, Allessandra [Author]; Matasci, Mattia [Author]; Schrepper, Andrea [Author]; Pfeil, Alexander [Author]; Bäz, Laura [Author]; Jung, Christian [Author]; Schulze, Paul Christian [Author]; Neri, Dario [Author]; Franz, Marcus [Author]
  • Published: 27 March 2021
  • Published in: International journal of molecular sciences ; 22(2021,7) Artikel-Nummer 3460, 19 Seiten
  • Language: English
  • DOI: 10.3390/ijms22073460
  • Identifier:
  • Origination:
  • Footnote:
  • Description: Abstract: Background and Aims: Pulmonary hypertension (PH) is a heterogeneous disorder associated with poor prognosis. For the majority of patients, only limited therapeutic options are available. Thus, there is great interest to develop novel treatment strategies focusing on pulmonary vascular and right ventricular remodeling. Interleukin 9 (IL9) is a pleiotropic cytokine with pro- and anti-inflammatory functions. The aim of this study was to evaluate the therapeutic activity of F8IL9F8 consisting of IL9 fused to the F8 antibody, specific to the alternatively-spliced EDA domain of fibronectin, which is abundantly expressed in pulmonary vasculature and right ventricular myocardium in PH. Methods: The efficacy of F8IL9F8 in attenuating PH progression in the monocrotaline mouse model was evaluated in comparison to an endothelin receptor antagonist (ERA) or an IL9 based immunocytokine with irrelevant antibody specificity (KSFIL9KSF). Treatment effects were assessed by right heart catheterization, echocardiography as well as histological and immunohistochemical tissue analyses. Results: Compared to controls, systolic right ventricular pressure (RVPsys) was significantly elevated and a variety of right ventricular echocardiographic parameters were significantly impaired in all MCT-induced PH groups except for the F8IL9F8 group. Both, F8IL9F8 and ERA treatments lead to a significant reduction in RVPsys and an improvement of echocardiographic parameters when compared to the MCT group not observable for the KSFIL9KSF group. Only F8IL9F8 significantly reduced lung tissue damage and displayed a significant decrease of leukocyte and macrophage accumulation in the lungs and right ventricles. Conclusions: Our study provides first pre-clinical evidence for the use of F8IL9F8 as a new therapeutic agent for PH in terms of a disease-modifying concept addressing cardiovascular remodeling. Keywords: pulmonary hypertension; monocrotaline; mouse; fibronectin; immunocytokines; interleukin-9
  • Access State: Open Access